Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | UNG | P13051 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8580569 | 0.87 | MAPT (0.44) | MAPTSMN1; SMN2L3MBTL1UNGMEN1 | |
| SCHEMBL9720583 | 0.84 | TDP1 (0.46) | MAPTSMN1; SMN2L3MBTL1UNGMEN1 | |
| SCHEMBL10389972 | 0.82 | SMN1; SMN2 (0.54) | MAPTSMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL4667605 | 0.80 | ALDH1A1 (0.57) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL19889497 | 0.80 | ALDH1A1 (0.42) | MAPTSMN1; SMN2L3MBTL1UNGMEN1 | |
| SCHEMBL4667601 | 0.80 | ALDH1A1 (0.57) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2954366 | 0.79 | UNG (0.68) | MAPTL3MBTL1UNGMEN1KMT2A | |
| SCHEMBL4895021 | 0.78 | EPHX2 (0.54) | MAPTSMN1; SMN2L3MBTL1UNGMEN1 | |
| SCHEMBL16618744 | 0.77 | CYP4F2 (0.54) | SMN1; SMN2KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL18890217 | 0.77 | PARP1 (0.57) | MAPTL3MBTL1UNGCYP2C19TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957073-B1 | MEDICINAL DRUG | OTSUKA PHARMA CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| EP-2612858-A1 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-12-20 | — | — | US | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-8263599-B2 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100210661-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | MAPT 4315/4885SMN1; SMN2 4313/4885L3MBTL1 502/4885 |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | MAPT 4294/4885SMN1; SMN2 4812/4885L3MBTL1 2115/4885 |
| US-20100210661-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | MAPT 4610/4885SMN1; SMN2 4827/4885L3MBTL1 2478/4885 |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | ROS1, CBR1, CBR3 | MAPT 4866/4885SMN1; SMN2 3224/4885L3MBTL1 533/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | MAPT 4163/4885SMN1; SMN2 3077/4885L3MBTL1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.